HR Execs on the Move

Cytokinetics

www.cytokinetics.com

 
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal muscle troponin activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Charles Yeary
 Director Talent Acquisition Profile
Rose Ann
 Associate Director Human Resources Profile
Julia Malasig
 Director of HR Systems and Operations Profile
Angela Yang Fu
 Associate Director, Global Supply Chain Profile
Ben Park
 Senior Director, Commercial Learning and Development Profile

Similar Companies

Diasome Pharmaceuticals Inc

Diasome Pharmaceuticals, Inc. is focused on the clinical and commercial development of breakthrough therapies for diabetes and obesity.

BC Biomedical Laboratories

BC Biomedical Laboratories Ltd. is a Surrey, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Paragon Biosciences

Paragon Biosciences invests in and launches biopharmaceutical companies to develop novel therapies for severe medical conditions which do not yet have adequate treatments. Our mission is to help people live longer, healthier lives. Paragon advances that mission through its contribution of Bioscience Innovation Capital(TM): For rare and complex diseases, Paragon analyzes the viability of potential therapies, invests in new biopharmaceutical companies to further develop promising treatments, catalyzes the progress of its portfolio companies through early-incubation services, and provides clinical and regulatory guidance by a team with a near-perfect track record of first-cycle novel drug approvals.

Empirico

Empirico is a venture-backed, next-generation therapeutics company founded on utilizing huge biological data sets, human genetics and programmable biology to power novel target discovery and development.

LogicBio

We are a genome editing company developing genetic medicines for the fight against rare pediatric diseases. GeneRide™ is a promoterless and nuclease-free approach to gene insertion which may improve the safety profile of AAV based gene therapies With GeneRide™, the therapeutic gene is site-specifically integrated into the genome allowing durable gene expression in dividing cells and mature tissues. Furthermore, therapeutic gene expression is regulated by the targeted locus so production can be limited to specific cell types.